Q-omics provides the consensus-scored FCGR1B profile across patient tissues and cancer cell-line models. FCGR1B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FCGR1B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FCGR1B RNA expression shows 19,535 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where FCGR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCGR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCGR1B survival associations across molecular data types. FCGR1B RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCGR1B RNA expression–survival associations across cancer types. High FCGR1B expression shows unfavorable associations in KIRC, UVM and LAML, but favorable associations in SKCM, CESC and CHOL. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FCGR1B RNA expression.
This table summarizes FCGR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FCGR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCGR1B shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, BRCA and COAD. The KIRC box plot shows higher FCGR1B RNA expression in tumor versus normal tissue (log2 FC = +1.225, t-test p < 0.001).
This table shows molecular features associated with FCGR1B in patient tissues and cancer cell lines. In patient samples, FCGR1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FCGR1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUAD.
